|  | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Study | Variable | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
Training set (untreated set) | 14-gene signature | 4.34 (1.86–10.1) | 0.001 | 3.16 (1.27–7.87) | 0.014 |
 | Age | 1.00 (0.97–1.03) | 0.853 | 1.00 (0.97–1.03) | 0.956 |
 | Tumor size | 1.91 (1.00–3.63) | 0.050 | 1.41 (0.68–2.91) | 0.353 |
 | Grade 2 | 2.21 (1.05–4.70) | 0.038 | 1.45 (0.65–3.22) | 0.360 |
 | Grade 3 | 1.72 (0.22–13.3) | 0.604 | 0.72 (0.09–6.00) | 0.759 |
Validation set (untreated set) | 14-gene signature | 4.71 (2.33–9.51) | <0.0001 | 4.02 (1.91–8.44) | 0.0002 |
 | Age | 1.03 (1.00–1.05) | 0.024 | 1.02 (0.99–1.04) | 0.193 |
 | Tumor size | 1.75 (1.25–2.46) | 0.001 | 1.37 (0.95–2.00) | 0.092 |
 | Grade 2 | 2.43 (1.10–5.40) | 0.029 | 1.25 (0.55–2.87) | 0.592 |
 | Grade 3 | 3.01 (1.23–7.39) | 0.016 | 1.11 (0.43–2.87) | 0.833 |
Tam-treated set | 14-gene signature | 3.61 (0.86–15.1) | 0.079 | 3.50 (0.58–21.2) | 0.172 |
 | Age | 1.04 (0.98–1.10) | 0.241 | 1.06 (0.98–1.14) | 0.166 |
 | Tumor grade | 1.50 (0.50–4.49) | 0.468 | NA | NA |